as of 03-05-2026 3:38pm EST
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | JERICHO |
| Market Cap: | 7.6M | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $9.18 | Next Earning Date: | 09-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -21.43 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
See how CURX stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CURX Curanex Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.